The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.
The European Commission will unveil its long-awaited EU pharmaceutical strategy on 24 November in an effort to improve access to affordable medicines and “harness the benefits of digital and emerging science and technology.”
The strategy will address both short-term challenges related to COVID-19 “and of course longer-term challenges linked to unmet medical needs,...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
